Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease
Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease
复制标题
DOI：
10.1016/j.urolonc.2004.10.005
复制
发表时间：
2004-11-01
影响因子：
2.7
通讯作者：
Moyad, MA
中科院分区：
文献类型：
--
作者：
Moyad, MA
向男性介绍心血管疾病(CVD)的标准和其他风险标志可能是困难的。但尤其是在泌尿肿瘤科，男性正在接受非心血管疾病的评估。目前对潜在的泌尿系肿瘤患者讨论心脏风险因素和评估的解释包括：(1)美国和世界上大多数地区男性的主要死因是心血管疾病；(2)最大的癌症预防试验(高风险或中等风险)的头号死因是心血管疾病：(3)前列腺癌患者的第一或第二死因是心血管疾病：(4)一些增加冠心病(CHD)风险的因素与增加前列腺癌风险的类似因素之间的关系不应被忽视；(5)通过降低胆固醇来降低心血管疾病的风险可能会降低某些泌尿系癌症的风险，如前列腺癌和肾癌。(6)在泌尿外科肿瘤科，监测患者生活方式改变是否成功的最好方法之一是监测心血管标志物。在一些对高危男性或被诊断为前列腺癌的男性的研究中也是如此。患者和临床医生需要知道他们的心血管风险标记物以及他们的癌症筛查测试结果，因为这两种情况之间可能存在严重的重叠。更好地了解这些基本标志物和风险评估方法，不仅可以在最坏的情况下降低心血管风险，而且在最好的情况下可以降低癌症确定性的风险或改善预后。(C)2004 Elsevier Inc.保留所有权利。
Introducing men to standard and other risk markers for cardiovascular disease (CVD) can be difficult. but especially in urologic oncology where men are being evaluated for non-cardiovascular conditions. The current explanations for discussing cardiac risk factors and assessment in potential urologic oncology patients include: (1) The primary cause of death of men in the U.S. and in most regions around the world is CVD; (2) the number 1 cause of death from the largest cancer prevention trials (high or average risk) is CVD: (3) the number 1 or 2 cause of death in men with prostate cancer is CVD: (4) a relationship between some factors that increase the risk of coronary heart disease (CHD) and similar factors that increase the risk of prostate cancer should not be ignored; (5) reducing the risk of CVD via cholesterol reduction may reduce the risk of certain urologic cancers such as prostate cancer and renal cell carcinoma. and (6) one of the potentially best methods to monitor the Success of lifestyle changes for the patient in urologic oncology is to monitor cardiovascular markers. as is the case in some studies of men at higher risk or diagnosed with prostate cancer. Patients and clinicians need to know their cardiovascular risk markers as well as they know the results of their cancer screening tests because there is a potentially profound overlap between the 2 conditions. A better knowledge of these basic markers and risk assessment methods may not only reduce cardiovascular risk in the worst case scenario, but in the best case scenario could reduce the risk or improve the prognosis of certainty of cancer. (C) 2004 Elsevier Inc. All rights reserved.